The presence of autoantibodies is associated with improved overall survival in lung cancer patients
Open Access
- 20 September 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1234847
Abstract
Objective: Autoantibodies have been reported to be associated with cancers. As a biomarker, autoantibodies have been widely used in the early screening of lung cancer. However, the correlation between autoantibodies and the prognosis of lung cancer patients is poorly understood, especially in the Asian population. This retrospective study investigated the association between the presence of autoantibodies and outcomes in patients with lung cancer.Methods: A total of 264 patients diagnosed with lung cancer were tested for autoantibodies in Henan Provincial People’s Hospital from January 2017 to June 2022. The general clinical data of these patients were collected, and after screening out those who met the exclusion criteria, 151 patients were finally included in the study. The Cox proportional hazards model was used to analyze the effect of autoantibodies on the outcomes of patients with lung cancer. The Kaplan-Meier curve was used to analyze the relationship between autoantibodies and the overall survival of patients with lung cancer.Results: Compared to lung cancer patients without autoantibodies, those with autoantibodies had an associated reduced risk of death (HRs: 0.45, 95% CIs 0.27~0.77), independent of gender, age, smoking history, pathological type, and pathological stage of lung cancer. Additionally, the association was found to be more significant by subgroup analysis in male patients, younger patients, and patients with small cell lung cancer. Furthermore, lung cancer patients with autoantibodies had significantly longer survival time than those without autoantibodies.Conclusion: The presence of autoantibodies is an independent indicator of good prognosis in patients with lung cancer, providing a new biomarker for prognostic evaluation in patients with lung cancer.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 38 references indexed in Scilit:
- EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung CancerCancer Prevention Research, 2011
- Clinical Relevance of Autoantibody Detection in Lung CancerJournal of Thoracic Oncology, 2011
- Peptide Mimic Isolated by Autoantibody Reveals Human Arrest Defective 1 Overexpression Is Associated with Poor Prognosis for Colon Cancer PatientsThe American Journal of Pathology, 2010
- Technical validation of an autoantibody test for lung cancerAnnals of Oncology, 2010
- The Impact of Autoimmune Diseases on the Incidence and Prognosis of Cutaneous Malignant MelanomaCancer Epidemiology, Biomarkers & Prevention, 2007
- Development of Autoantibodies before the Clinical Onset of Systemic Lupus ErythematosusNew England Journal of Medicine, 2003
- Autoantibodies in Systemic Lupus Erythematosus — There before You Know ItNew England Journal of Medicine, 2003
- Does the Immune System See Tumors as Foreign or Self?Annual Review of Immunology, 2003
- Evidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testingArthritis Care & Research, 2002
- Natural Autoantibody to MUC1 Is a Prognostic Indicator for Non–Small Cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2000